Opens in a new tab

STADAPHARM v Novartis (CFI, 3 February 2025)

Date3 February 2025
CourtCFI
DivisionMilan (IT) Central Division- Section
Type of actionApplication RoP262.1 (b)
Case number(s)UPC_CFI_698/2024
Registry referenceUPC_CFI_698/2024 · App_68658/2024
PartiesSTADAPHARM GmbH v. ACCORD HEALTHCARE B.V., ACCORD HEALTHCARE S.L.U., ACCORD HEALTHCARE LIMITED, Novartis AG

Official decision (PDF) · UPC registry entry

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

By an order of 3 February 2025 (UPC_CFI_698/2024, ORD_68703/2024), the Milan Central Division (Judges Postiglione, presiding and rapporteur, Knijff and Werner) dismissed the request by STADAPHARM, a non-party, for access to the file in the action for a declaration of non-infringement brought by Accord Healthcare against Novartis on EP 2 501 384. Novartis had obtained provisional measures in Germany against STADAPHARM on the same patent, which were under appeal. The order matters for competitors in parallel litigation: access under Rule 262.1(b) cannot be used as a tactical tool against the proprietor.

Question

Can a competitor engaged in parallel national litigation obtain access to the pleadings in a UPC non-infringement action, and are written pleadings without an electronic signature valid?

Decision

Novartis’s pleadings were valid: Rule 4.1 does not require an electronic signature where the filing is unequivocally traceable to the lawyer (paragraph 6). Access was refused: only Accord’s documents were on file at the date of the request, and STADAPHARM itself described them as of no use (paragraph 7). Balancing against the integrity of proceedings weighed against access sought to expose Novartis’s defence and influence the German appeal (paragraphs 8 to 14). There was no risk of irreconcilable decisions between a non-infringement ruling and provisional measures (paragraph 15). Absent a decision on the merits, no costs order was made under Rule 150 (paragraph 16).

Key points for practice

Provisions applied

Agreement on a Unified Patent Court
Art. 10, 44, 45 and 73(2)(b)
Rules of Procedure
Rules 4.1, 150, 220.2, 224.1(b), 262, 262A and 264
Case law cited
Court of Appeal, 10 April 2024, Ocado v AutoStore (UPC_CoA_404/2023), Court of Appeal, Abbott v Sibio (UPC_CoA_480/2024 and UPC_CoA_481/2024), Nordic-Baltic Regional Division (UPC_CFI_8/2023), Milan Central Division (UPC_CFI_380/2024), Paris Central Division (UPC_CFI_412/2023)

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Decisions in the same proceedings

Going further

Lexicon: Written procedure (UPC), Confidentiality club.

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

  • UPC_CFI_698/2024 official number

Follow this case

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

No other decision in the corpus bears the same case number, and no appeal is documented in the corpus to date.

What the record states

Nature of the act
Application RoP262.1 (b)
Outcome (Dhenne Avocats summary)
La section de Milan de la division centrale rejette la demande d'accès de STADAPHARM, faute d'intérêt propre et en raison du risque de pression sur Novartis, et valide les écritures de celle-ci.
Appeal
No appeal documented in the corpus, this does not mean that no appeal was lodged.
Instance
First-instance decision, whether it has become final is not recorded.

Patents mentioned

Related decisions cited in the analyses

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 2 501 384Mentioned in the analysis (role not qualified)
Also mentioned in 4 other decision(s): Novartis v ZENTIVA PORTUGAL (CFI, 31 July 2025) · STADAPHARM v ACCORD HEALTHCARE (CoA, 14 April 2025) · Accord Healthcare v Novartis (CFI, 10 April 2025) · ZENTIVA K.S. v NOVARTIS (CFI, 21 March 2025)
not recordednot recordednot recordedEspacenet
links not checked
mentioned in: Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.